Together to accelerate innovation
“ The objective of the Carnot Institute CALYM is to promote innovation in lymphoma research and to accelerate its transfer to clinics and the health industry through public/private partnerships. The CALYM R&D offer is positioned in a global pharmaceutical and biotechnological market that is growing strongly and that has been taking a strategic turn for several years now, requiring essential biological, clinical and technological expertise from the academic sector. In order to meet these market requirements, CALYM is based on a unique position in the whole R&D value chain: from the identification of new cellular targets, to international phase III clinical trials and beyond.”
Bertrand Nadel, Director of the Carnot Institute CALYM
A unique positioning across the entire R&D value chain
Making major discoveries on lymphomas and transforming them into therapeutic innovation.
Transforming therapeutic innovations in medicine for the benefit of patients suffering from lymphomas.
Together against lymphomas
Independent network of professionals performing clinical research on lymphomas, acknowledged as a Cooperating Group.
Operational structure for lymphoma research managing the LYSA projects.
Consortium dedicated to partnership-based lymphoma research, including the LYSA, the LYSARC and 18 laboratories.